GeneCentric highlights LSP 120 at lung cancer conference
DURHAM, N.C.—This year's World Conference on Lung Cancer, held in Denver in early September, saw GeneCentric Diagnostics Inc. present new data on LSP 120, its lung cancer subtyping product, which was developed using the company's Cancer Subtyping Platform. The presentation was titled “Survival Differences of Adenocarcinoma Lung Tumors with Squamous Cell Carcinoma or Neuroendocrine Profiles by Gene Expression Subtyping,” and Dr. Hawazin Faruki, vice president for clinical development at GeneCentric, served as presenter.
“LSP 120 has the potential to identify a subset of lung adenocarcinoma patients with poor prognosis, as compared to other lung adenocarcinoma patients,” said Faruki. “Reduced survival may be due to inherent features of the tumor and to variable response to standard lung adenocarcinoma therapeutic management. LSP 120 subtyping may prove to be an important tool in stratification strategies for improved drug trial design and patient care.”